DongKook Pharmaceutical Co. Ltd (086450) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of DongKook Pharmaceutical Co. Ltd stock KRW 28,372, price KRW 23,550, upside +20.5%, quality 57 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range 12,623 KRW – 29,900 KRW · fair‑value band 14,660 KRW – 38,321 KRW · the 23,550 KRW price screens below the 28,372 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow DongKook Pharmaceutical Co. in your weekly email
Every Wednesday you see whether DongKook Pharmaceutical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
DongKook Pharmaceutical Co., Ltd. provides pharmaceutical products in South Korea and internationally.
Show moreShow less
It produces active pharmaceutical ingredients, including propofol, streptokinase, and teicoplanin; disposable syringes; and pills, capsules, and ointments, as well as small volume parentral, large volume parentral, and lyophilized injectable drug injections.
The company also offers Teicon, Durakinase, and Lorelin Depot injections; produces various natural product materials, such as black cohosh extract and magnolia extract comprises ETIZM and TECA; and natural herb medicines.
In addition, it provides general and prescription-based drugs; medical devices; ETC and cosmetic products; and quasi drugs that include lipossol hydrocare bandage.
DongKook Pharmaceutical Co., Ltd. also exports its products to approximately 40 countries, including Japan, Europe, Central and South America, and India. The company was formerly known as UEC & Co., Ltd. and changed its name to DongKook Pharmaceutical Co., Ltd. in March 1982.
DongKook Pharmaceutical Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
Stock analysis
DongKook Pharmaceutical Co. Ltd (086450) currently trades at 23,550 KRW, while our model-based Fair Value estimate is 28,372 KRW, implying the stock looks roughly 17% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 30,366 KRW per share, and 13 of the 26 models we run sit above the 23,550 KRW price.
Bear case: the Asset-Based group reads lowest at 3,745 KRW, and 13 of the 26 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 14,660 KRW (bear) to 38,321 KRW (bull), the price of 23,550 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
DongKook Pharmaceutical Co. Ltd reported revenue of 927B KRW in FY2025 versus 594B KRW in FY2021, a compound +11.8%/yr. Reported net income was 66.0B KRW in FY2025, compounding +7.0%/yr from FY2021.
Key figures
Market cap 1.0T KRW (≈ $767M) Small · P/S ratio 1.69 · Dividend yield 0.7% · Net margin 9.1% · Return on equity 994% · Return on assets (EBIT) 8.7% (5-year average) · Operating margin 11.1% · Revenue (TTM) 646B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).
What moves the price
The share trades about 21% below its 52-week high and 43% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at 20%, 086450 screens cheaper than that median.
Fair Value models
Bear14,660 KRWFair Value 28,372 KRWBull38,321 KRW
Price 23,550 KRW · Upside +20.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.73/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+14.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.6%
Start year 2020 (pandemic). Over 10 years: +13.6% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+3.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.2%
Dividend (yield on the price)0.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.3.2% vs 4.9%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 10%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+29.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +27.1% a year for the price.
Compare DongKook Pharmaceutical Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 54 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside+20.5% · Above median
Profitability
Return on assets6.2% · Top 25%
Net margin (12 months)9.1% · Above median
Operating margin (12 months)11.1% · Above median
Growth and dividend
Revenue growth (quarter YoY)10.1% · Below median
Dividend yield (12 months)0.7% · Below median
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is DongKook Pharmaceutical Co. Ltd (086450) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of 28,372 KRW versus a price of 23,550 KRW, about +20% upside (undervalued).
What is the fair value of 086450?
Our model-based fair value for DongKook Pharmaceutical Co. Ltd is 28,372 KRW (as of Nov 6, 2026), built from audited fundamentals. The current price: 23,550 KRW.
What is the quality score of 086450?
DongKook Pharmaceutical Co. Ltd has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DongKook Pharmaceutical Co. Ltd (086450)?
Our model-based price target is the fair value of 28,372 KRW (as of Nov 6, 2026) from 26 valuation models. Cautious scenario 14,660 KRW, optimistic scenario 38,321 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the DongKook Pharmaceutical Co. Ltd stock forecast for 2026?
Our models put fair value at 28,372 KRW, about +20% upside versus a price of 23,550 KRW (undervalued). Cautious scenario 14,660 KRW, optimistic scenario 38,321 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of DongKook Pharmaceutical Co. Ltd (086450)?
DongKook Pharmaceutical Co. Ltd reported trailing-twelve-month revenue of about 646B KRW (latest available figure, as of Nov 6, 2026).
Does DongKook Pharmaceutical Co. Ltd pay a dividend?
DongKook Pharmaceutical Co. Ltd currently shows a dividend yield of 0.73% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of DongKook Pharmaceutical Co. Ltd (086450)?
DongKook Pharmaceutical Co. Ltd has a dividend yield of 0.7%. A dividend has been paid every year since at least 2007. Our assessment: Safety not assessed. Payout ratio and cash coverage are not available, so we do not judge how safe this dividend is.
What growth is priced into DongKook Pharmaceutical Co. Ltd (086450)?
For today's price to be fair in a discounted-cash-flow model, DongKook Pharmaceutical Co. Ltd would have to grow free cash flow by +29.7 % per year for five years (discount rate 11.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +10.6 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of 086450 use?
Our models discount DongKook Pharmaceutical Co. Ltd at 11.4 %: a base by market capitalisation (small), damped by beta 0.92, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For DongKook Pharmaceutical Co. Ltd that is +29.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.4 %) and the same formula as our fair value.
How much growth has DongKook Pharmaceutical Co. Ltd (086450) delivered so far?
Over the past 5 years revenue at DongKook Pharmaceutical Co. Ltd grew +10.6 % a year. The price currently implies free-cash-flow growth of +29.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of DongKook Pharmaceutical Co. Ltd (086450) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into DongKook Pharmaceutical Co. Ltd (+29.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of DongKook Pharmaceutical Co. Ltd (086450)?
The free-cash-flow yield on the price is 2.18 %: that much free cash flow DongKook Pharmaceutical Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of DongKook Pharmaceutical Co. Ltd (086450)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DongKook Pharmaceutical Co. Ltd it is 28,372 KRW per share (as of Nov 6, 2026), against a price of 23,550 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is DongKook Pharmaceutical Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 086450 trades below its calculated fair value: price 23,550 KRW, fair value 28,372 KRW, a gap of about +20% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 086450?
No. The price is what the market pays today (23,550 KRW); the fair value is what the company's own numbers justify (28,372 KRW). For DongKook Pharmaceutical Co. Ltd the two are 4,822 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is DongKook Pharmaceutical Co. Ltd worth?
The market values DongKook Pharmaceutical Co. Ltd at about 1.0T KRW (market capitalisation, as of Nov 6, 2026). Per share that is 23,550 KRW; our models calculate a fair value of 28,372 KRW per share.
What do the bullish and bearish scenarios say about 086450?
Our models span a range for DongKook Pharmaceutical Co. Ltd: cautious scenario 14,660 KRW, base 28,372 KRW, optimistic 38,321 KRW per share (as of Nov 6, 2026, price 23,550 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of DongKook Pharmaceutical Co. Ltd (086450)?
Balance-sheet figures for DongKook Pharmaceutical Co. Ltd (as of Nov 6, 2026): debt of 0.02 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 086450 from its 52-week high?
DongKook Pharmaceutical Co. Ltd trades at 23,550 KRW, about 21% below its 52-week high of 29,900 KRW and 43% above the low of 16,420 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 28,372 KRW is for.
Which stocks are comparable to DongKook Pharmaceutical Co. Ltd?
From the same area (Healthcare) we also value ST Pharm Co, Caregen Co, Oscotec Inc, SHUKRAPHAR, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DongKook Pharmaceutical Co. Ltd stock attractive at the current price?
The data as of Nov 6, 2026: price 23,550 KRW, calculated fair value 28,372 KRW (+20%), Quality Score 57/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 086450 calculated?
We run DongKook Pharmaceutical Co. Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 28,372 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. DongKook Pharmaceutical Co. Ltd currently trades 17% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DongKook Pharmaceutical Co. Ltd (086450)?
The closing price on Nov 6, 2026 was 23,550 KRW. Our model-based fair value is 28,372 KRW, about +20% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DongKook Pharmaceutical Co. Ltd right now?
The model range is unusually wide (14,660 KRW to 38,321 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (57/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of DongKook Pharmaceutical Co. Ltd
How large is the market capitalisation of DongKook Pharmaceutical Co. Ltd (086450)?
The market capitalisation of DongKook Pharmaceutical Co. Ltd is 1.0T KRW (≈ $767M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DongKook Pharmaceutical Co. Ltd (086450)?
The price-to-sales ratio of DongKook Pharmaceutical Co. Ltd is 1.69 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of DongKook Pharmaceutical Co. Ltd (086450)?
The dividend yield of DongKook Pharmaceutical Co. Ltd is 0.7%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of DongKook Pharmaceutical Co. Ltd (086450)?
The net margin of DongKook Pharmaceutical Co. Ltd is 9.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DongKook Pharmaceutical Co. Ltd (086450)?
The return on equity (ROE) of DongKook Pharmaceutical Co. Ltd is 994% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DongKook Pharmaceutical Co. Ltd (086450)?
On an EBIT basis the return on assets of DongKook Pharmaceutical Co. Ltd is 8.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DongKook Pharmaceutical Co. Ltd (086450)?
The operating margin of DongKook Pharmaceutical Co. Ltd is 11.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DongKook Pharmaceutical Co. Ltd (086450)?
Revenue at DongKook Pharmaceutical Co. Ltd is growing +10.1% versus a year earlier (3y avg +11.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DongKook Pharmaceutical Co. Ltd (086450)?
Earnings per share at DongKook Pharmaceutical Co. Ltd are growing +38.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does DongKook Pharmaceutical Co. Ltd (086450) carry?
The net debt of DongKook Pharmaceutical Co. Ltd is 11.6B KRW (fiscal year 2025, ≈ 0.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch DongKook Pharmaceutical Co. Ltd in the live analysis
One click puts DongKook Pharmaceutical Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026